| 2.005 -0.175 (-8.03%) | 05-12 12:07 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.13 |
1-year : | 3.71 |
| Resists | First : | 2.68 |
Second : | 3.18 |
| Pivot price | 2.07 |
|||
| Supports | First : | 1.87 |
Second : | 1.56 |
| MAs | MA(5) : | 2.08 |
MA(20) : | 2.18 |
| MA(100) : | 2.76 |
MA(250) : | 4.85 |
|
| MACD | MACD : | -0.3  |
Signal : | -0.3 |
| %K %D | K(14,3) : | 34 |
D(3) : | 32.9 |
| RSI | RSI(14): 38.5 |
|||
| 52-week | High : | 21 | Low : | 1.32 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ACXP ] has closed above bottom band by 7.7%. Bollinger Bands are 83.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.19 - 2.2 | 2.2 - 2.21 |
| Low: | 2.02 - 2.04 | 2.04 - 2.05 |
| Close: | 2.16 - 2.18 | 2.18 - 2.2 |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Tue, 12 May 2026
ACXP: Advanced ibezapolstat clinical trials in CDI, strengthened cash, and leveraged new FDA guidance - TradingView
Tue, 12 May 2026
ACURX PHARMACEUTICALS ($ACXP) Releases Q1 2026 Earnings - Quiver Quantitative
Tue, 12 May 2026
Single-drug C. diff trial tests treatment plus relapse prevention - Stock Titan
Tue, 12 May 2026
[EFFECT] Acurx Pharmaceuticals, Inc. SEC Filing - Stock Titan
Mon, 11 May 2026
Acurx Pharmaceuticals (ACXP) trims Q1 loss but flags going-concern risk - Stock Titan
Mon, 11 May 2026
ACXP Q1'26 Earnings: EPS estimate is (1.20) USD - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 6.4 (%) |
| Shares Short | 95 (K) |
| Shares Short P.Month | 1,050 (K) |
| EPS | -5.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.24 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -87.6 % |
| Return on Equity (ttm) | -270.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.37 |
| PEG Ratio | 0 |
| Price to Book value | 0.86 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|